Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

about

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Item

http://www.wikidata.org/entity/Q58761583

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@en

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@nl

type

Item

label

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@en

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@nl

prefLabel

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@en

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@nl

P1476

Immune checkpoint inhibitors a ...... osttransplant cyclophosphamide

@en

P2093

Douglas E Gladstone

http://www.w3.org/2001/XMLSchema#string

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Ivana Gojo

http://www.w3.org/2001/XMLSchema#string

Kenneth R Cooke

http://www.w3.org/2001/XMLSchema#string

Laura K Schoch

http://www.w3.org/2001/XMLSchema#string

Lode J Swinnen

http://www.w3.org/2001/XMLSchema#string

Mark Levis

http://www.w3.org/2001/XMLSchema#string

Nina D Wagner-Johnston

http://www.w3.org/2001/XMLSchema#string

Philip Imus

http://www.w3.org/2001/XMLSchema#string

Richard F Ambinder

http://www.w3.org/2001/XMLSchema#string

P2860

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.

1994 Consensus Conference on Acute GVHD Grading

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

P304

2226-2229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOODADVANCES.2018019208

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30190282

http://www.w3.org/2001/XMLSchema#string

P932

6134225

http://www.w3.org/2001/XMLSchema#string